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IN A RECENT EVALUATION of thoracic duct drain-
age for renal transplantation, we suggested that 
the optimal use of the lymphoid depletion should 
include pretreatment for intervals influenced by 
the absence, presence or kinds of antibodies in the 
serums of the recipients (28); These recommen-
dations which were then speculative have since 
been tested in 27 consecutive cadaveric renal trans-
plantations. During follow-up periods of one to 
six months, only six of the 27 patients have had a 
rejection, which in five instances was reversed. 
The virtual elimination of early graft loss has 
made cadaveric renal transplantation a more 
predictable venture at our institution than at any 
time in the past. The clinical and serologic obser-
vations herein reported suggest the possibility of 
further improvements by small adjustments in the 
duration of preoperative thoracic duct drainage. 
METHODS 
The patients were ten to 61 years old (Table 
I) and included three who had diabetes, several 
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who had ischemic heart.disease and past myocar-
dial infarctions and 'three who were undergoing 
retransplantation. The causes of the renal failure 
were variable, as in our past experience, with 
chronic glomerulonephritis being the most com-
. mono All of the recipients had been receiving, 
chronic dialysis. 
Antigens of the HLA-A, B and DR loci were 
determined for the recipients and their-cadaveric 
donors (30). Since the typing results were not 
used in an attempt to obtain tissue compatible, 
recipients for the donors, the random matches 
were poor (Table I). :-
Antibody analysis. Cytotoxic antibodies in the 
serums of the recipients were determined before': 
starting thoracic duct drainage and every one to 
three weeks thereafter. The antibodies were de-
tected by cross matching the serums against the 
lymphocytes of 30 healthy donors (30). If anti-
bodies were present, they were further analyzed 
and categorized as anti-T and anti-B lymphocyte 
antibodies under warm and cold testing condi-
tions (30). 
At transplantation, standard direct cross 
matches were done between the recipient serums 
and donor 1 ym phocytes (30). All 27 patients were 
given kidneys from cross match negative donors. 
Timing of thoracic duct drainage. Previously 
recommended management scheme is summa-
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rized in Table II. Patients whose serums pos-
sessed no antibodies or only cold antibodies 
against the panel were scheduled for preoperative 
lymph drainage for three weeks; those with warm 
antibodies were pretreated for at least 30 days. 
In this series, recipients usually were avoided 
who possessed broadly reacting warm anti-T an-
tibodies. Because of their propensity to hyper-
acutely reject kidney grafts, such patients should 
be placed in a separate category if new immuno-
suppressive techniques are to be evaluated (28). 
Nevertheless, Patients 1, 2 and 27 had warm an-
ti-T antibodies against 11, 47 and 75 per cent, 
respectively, of the screening panel (Table I). 
Thoracic duct drainage was established in the 
neck as described before (12, 25, 28). As the se-
ries of 27 patients was compiled, no other 
recipients had attempts at thoracic duct drainage 
which failed. The vitally important details of 
operative and postoperative management have 
been thoroughly outlined elsewhere, including 
lymph collection, lymphocyte removal by cen-
trifugation and lymph return intravenously. 
Other management. To achieve reasonable 
conformity with the timing depicted in Table II, 
unusual reliance for the cadaveric organs was 
placed on regional and national organ procure-
ment networks. In five of the grafts, function was 
delayed for three to 15 days, necessitating one to 
five dial yses postoperatively. 
Azathioprine and prednisone were begun on 
the day of transplantation. Nine of the 27 recip-
ients also had courses of antithymocyte globulin 
for at least five days. The daily azathioprine dos-
age was designed to avoid leukopenia. The pred-
nisone dose was 200 milligrams on the first day. 
Thereafter, daily reductions by 10 milligrams 
were made if rejection did not supervene, until a 
dose of 40 milligrams was reached in 16 days. 
Further reductions were individualized, usually 
with monthly decrements of 5 milligrams. 
Evaluation of rejection. Rejection was defined 
as a secondary rise of creatinine of more than 25 
per cent above base line, along with the other bio-
chemical findings of renal failure. The character-
istic physical signs of rejectio~ were looked for. 
Radionuclide scanning was routinely obtained 
and was particularly valuable in assessing the 
course of patients in whom the grafts initially 
had acute tubular necrosis, as described by Sta-
bles and associates (23). 
RESULTS 
The details in individual patients are shown in 
Table I, including the duration of thoracic duct 
drainage, amount of lymph drainage and num-
bers of cells removed. In each of the 27 patients, 
the numbers of lymphocytes obtained daily mark-
edly diminished during the pretreatment period. 
Most of the thoracic duct fistulas were discontin-
ued within a month after transplantation. The 
inability to obtain cadaveric kidneys exactly 
when needed introduced a variability into the 
pretreatment time upon which a division of pa-
tients was made for analysis. 
Pretreatment of 26 to 58 days. These 14 pa-
tients included four who had preformed warm 
antibodies and who had prolonged lymph drain-
age for that reason. The other ten had more pre-
treatment than planned because donors did not 
become available on schedule. Patient 3 had an 
abortive initial attempt at transplantation which 
was abandoned because of traction injuries of 
both donor renal arteries. Definitive transplanta-
tion was carried out a few days later. 
There was one minor rejection during the fol-
low-up periods of one to six months. All of the 12 
surviving patients have normal kidney function 
(Table I). Their maintenance steroid dosages 
are variable, according to the duration of follow-
up study (Table I). 
In the first 14 consecutive patients, antibodies 
against the lymphocyte panel were restudied two 
weeks after transplantation. Twelve of the 14 pa-
tients then had warm anti-B antibodies (Table 
Ill) but these reacted against more than half of 
the donor panel in only one instance. Included 
were Patients 1, 2, 24 and 25 who had broadly 
reacting warm anti-B or anti-T antibodies (Ta-
ble I) before 58,55,43 and 33 days, respectively, 
of thoracic duct drainage. As reported before 
(28), the antibodies were diminished during 
pretreatment but usually not eliminated. These 
four recipients had negative standard cross 
matches with their donors. By two weeks after 
transplantation, three of the four patients had a 
return of warm anti-B as well as anti-T anti-
bodies. However, the resurgent antibodies were 
broadly reacting in only one instance. At two 
weeks, cold anti-B antibodies were found in the 
serums of four of the 14 patients (Table III) 
compared with an equal incidence of four in 14 
before transplantation. 
There were two deaths (Table I), a mortality 
of 13 per cent. Patient 5 was a 57 year old wom-
an with known coronary artery disease who had 
been discharged after transplantation with nor-
mal renal function. A few weeks later, she died in 
an outlying hospital, immediately after she un-
fortunately was administered 2 grams of lido-
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TABLE II-STEPS IN MANAGEMENT 
STEP 1. Accurate assessment of antibodies against screening panel 
Possibililirs are: 
A. Antibody-free 
B. Antibodies present· 
I. Anti-T. warm ... worst 
2. Anti-B. warm ... bad 
3. Anti-B. cold ... good? 
STEP 2. Time of thoracic duct drainage pretreatment leading to 
transplantation from a cross match negative donor 
A. Patient antibody-free or with cold antibodies ... 21 days 
B. Patient with warm anti-Tor warm anti-B antibodies 
. . . <!35 days 
STEP 2 (alternative). Time of thoracic duct drainage pretreatment 
leading to transplantation from a cross match positive donor 
A. Patient with warm anti-B antibodies ... ~ 35 days 
B. Delay transplantation in patients with warm anti-T 
antibodies until titer is below 1:4 
~ anlibodies are IgO. Cold antibodies are IgM. 
caine intravenously during the treatment of a 
cardiac arrhythmia. An autopsy was denied. 
Patient 13 died from a systemic viral infection, 
including diffuse pneumonitis two months after 
transplantation, despite prolonged ventilatory 
support and drastic reduction of steroid therapy. 
The kidney did not show evidence of rejection. 
Pretreatment of 77 to 23 days. All but one of 
these 13 patients were free of warm antibodies 
preoperatively. Five of the 13 had rejection de-
velop from eight to 30 days after transplantation, 
necessitating secondary increases of steroid ther-
apy. The rejections were reversed without the 
necessity for dialysis, with one exception. The lat-
ter patient underwent retransplantation. 
The 12 surviving patients have renal function 
which is normal in those who escaped rejection 
but variable in the five who did not (Table I). 
The penalty for rejection in the latter five re-
cipients has been a higher maintenance dosage of 
prednisone (Table I). 
By two weeks after transplantation, 11 of the 
13 patients had warm anti-B antibodies develop, 
which in seven of the recipients were reactive 
against more than half of the lymphocyte panel 
(Table III). All five of the rejections were in the 
TABLE III.-ASSOCIATION BETWEEN THORACIC DUCT 
DRAINAGE AND PRODUCTION OF ANTI-B ANTI-
BODIES TO A PANEL TWO WEEKS AFTER TRANS-
PLANTATION 
No. 
B Warm antibody 
TD D 18-23 days.. \3 
TDD 26-58 days .. 14 
B Cold antibodies 
TD D 18-23 days.. 13 
TDD 26-58 days .. 14 
TOD. ThoraCIC duct drainage. 
·Considered to ~ negative. 
0-5 6-15 
per cen t" per cen t 
2 
2 
4 
10 
2 
7 
7 
1 
16-50 
percent 
2 
4 
2 
3 
>50 
percent 
7t* 
1 
o 
o 
tFour of the five palie~~s with rejection were in this group. 
t;The resuhs were Significant. p<O.05, in comparison with those with pretreat· 
ment for 26-S8 days. 
latter group of seven patients. The ability of pa-
tients with short pretreatment to form broadly re-
active warm antibodies was significantly greater 
than that of recipients pretreated for longer pe-
riods (Table III). In addition, cold antibodies 
were more frequently observed after the shorter 
preparation (Table III). 
One of the 13 patients died of acute pancreati-
tis, one month after transplantation. An autopsy 
was denied . 
DISCUSSION 
The 27 cadaveric kidney recipients in this se-
ries had more effective immunosuppression than 
did similar patients treated by us at any time in 
t~e past.. Only one of the organs was lost to rejec-
tIOn durmg follow-up study of one to six months. 
The influence of thoracic duct drainage was so 
obvious that it is hard to explain the neglect by 
surgeons of this potent immunosuppressive mea-
sure, which was first used in human renal trans-
plantation by Franksson (4) and Newton (18) 
more than t 5 years ago. Subsequent clinical tri-
als with variable results were reported by 
F:anksson (5, 6), Tilney (3 t ), Murray (t 7), 
Fish (3), Sarles (21 ), Archimbaud (1 ), Traeger 
(32), Martelli (t 4 ), Ianhez (7) and Sonoda 
(22) and their associates. The procedure was not 
accepted by transplantation surgeons, including 
those who had tried it, and it was generally aban-
doned. Further inq uiry into the use of thoracic 
duct drainage has been done mainly by Walker 
(33» Johnson (t 0) and Niblack (t 9) and their 
associates, by Kaplan (11) and by us (25, 28). 
The missed opportunities with thoracic duct 
drainage in the past were caused by gaps in 
know~edge which have since been filled and by 
techntcal problems which have since been solved. 
The ti~ing of the immune depression caused by 
thoraCIC duct drainage in human beings was not 
well defined until Machleder and Paulus (t 3 ) 
showed that nearly three weeks were required 
for major immunologic changes and that these 
changes continued to deepen for an additional ten 
or 15 days. The sequence was far longer than 
had been observed in rats by MacGregor and 
Gowans (15, 16). Moreover, although MacGreg-
or and Gowans (15, t 6) had demonstrated sup-
pression in rats of both humoral and cell medi-
ated immunity, this dual effect in humans was 
not unequivocally established until the reports by 
Machleder and Paulus (13) and by us (25, 28). 
Finally, the exploitation of this information 
depended upon increasing the reliability of 
chronic lymph drainage. This was achieved by 
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Koep and associates ( 12) using improved opera-
tive and management techniques. 
The precision with which thoracic duct drain-
age could be applied was further increased by 
developments in transplantation serology. The 
cytotoxic antibodies that may be found in re-
cipient serums before or after transplantation 
were recently characterized on the basis of their 
reactivity against homologous T -lymphocytes and 
B-Iymphocytes at warm and cold temperatures 
(2, 8, 30). Subsequent reports about the sig-
nificance of these antibodies have been so con-
flicting that it is difficult to summarize this con-
fusing literature. Our own experience has been 
that warm anti-T antibodies cause hyperacute 
rejection if present preoperatively (2, 8, 30), that 
pre-existing warm anti-B antibodies diminish 
the chances of long term function (8,9) and that 
the development of either warm anti-Tor anti-B 
antibodies after transplantation jeopardizes the 
prognosis (8). The so-called cold antibodies have 
been thought to be innocuous or possibly even 
enhancing (2, 8, 30). The variable duration of 
pretreatment with thoracic duct drainage (Table 
II) was designed to reduce pre-existing warm 
antibodies and to curb the fresh development of 
these antibodies in response to transplantation. 
More sophisticated and discriminating tests 
could have been used for immune assessment and 
monitoring, but the antibody analysis had the 
merit of simplicity. 
The validity of this approach was supported 
by the experience herein reported. It was evident 
that many of the patients were pretreated for too 
short a time. Grafts placed into recipients condi-
tioned by approximately three weeks of thoracic 
duct drainage still could provoke strong antibody 
responses in recipients who were previously an-
tibody-free. These organs were jeopardized by a 
38 per cent incidence of significant, although 
usually reversible, rejection. In contrast, anti-
body responses were blunted, and early rejection 
was almost eliminated when thoracic duct drain-
age was in effect for four weeks or longer. Thus, 
we have modified our previous recommendations 
(Table II) in the direction of more protracted 
pretreatment (Table IV). 
With pretreatment for four or more weeks, 
early rejection was almost totally prevented. It 
would be surprising if the same objective could 
not be achieved by preopel'ative lymphoid deple-
tion with other means for a period of several 
weeks. An obvious possibility is mechanical re-
moval of lymphocytes from the peripheral blood, 
a procedure for which instrumentation is already 
TABLE IV.-REVISED STEPS IN MANAGEMENT 
STEP 1. Antibody as""ssment, same as Table II 
STEP 2. Duration of pretreatment, cross match negative donor 
A, Antibody-free or cold antibodies ... ~OU days 
B, Warm anti-T or anti-B antibodies ... 2:35 days 
STEP 2 (alternative). Duration of pretreatment, cross match posi-
tive donor, same as Table II 
commercially available. The technique of total 
lymphoid irradiation, described by Strober and 
associates (29) is a variation of the same theme, 
so would be pretransplantation conditioning 
with powerful antilymphocyte serums and globu-
lins, an approach that has been made impractical 
in patients by immune reactions to the heterol-
ogous protein (27). With any of these methods, 
treatment in the pretransplantation period will 
be essential for maximum benefit. Even with as 
potent a lymphoid depleting tool as thoracic duct 
drainage, much of the value is lost if treatment is 
begun contemporaneous with transplantation, as 
was shown with our own systematic trial (25, 
28) in which the results were distinctly inferior 
to those herein reported. 
The potential value of pretreatment is not nec-
essarily limited to the foregoing specific lym-
phoid depleting techniques. In the early days of 
our program, almost all human kidney recipients 
were given azathioprine for eight to ten days 
before transplantation. The practice was based 
upon analogous canine experiments in which 
average homograft survival was thereby doubled 
over that obtained when the drug was begun on 
the day of operation (24). Gradual abandon-
ment of the policy of preoperative treatment of 
the patients in our series with azathioprine and 
often with steroids may have been a systematic 
error, inasmuch as other immunosuppressive ad-
juncts to condition the recipients were not being 
substituted. Wilson and Kirkpatrick (34) and 
Opelz and colleagues (20) were among the first 
to appreciate the role of intrinsic immunologic 
reactivity in determining the early postoperative 
course. If the patients were immunologically re-
active, pretreatment with any effective immu-
nosuppressive agent would reduce this adverse 
factor, apart from coincidentally ameliorating 
undetected presensitization states by erasure of 
immunologic memory. 
Unfulfilled promises have been so common in 
renal transplantation that cautionary notations 
are automatic and, particularly so, if long follow-
up study periods are not available. In the patients 
in our series, it remains to be seen if a delayed 
immunologic rebound will cause major kidney 
losses long after discontinuance of thoracic duct 
drainage. However, Walker (33) and Johnson 
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( 10) and their associates have not seen a catch-
up deterioration of grafts in patients observed for 
two to five years after preoperative and postoper-
ative thoracic duct drainage. It seems likely that 
the poorly understood change in host-graft rela-
tionship (26) which has made clinical transplan-
tation practical will be expedited rather than 
hindered by properly timed thoracic duct drain-
age. If so, improvements in early graft survival 
should be translated into better long term results. 
SUMMARY 
Twenty-seven consecutive recipients of cada-
veric kidneys, including five with pre-existing 
warm cytotoxic antibodies, were treated with 
thoracic duct drainage before and after trans-
plantation. Fourteen patients who had lymph 
drainage for 26 to 58 days before transplantation 
had minor cytotoxic antibody responses after 
grafting, even if the antibodies had been present 
before therapy. Only one of the 14 recipients had 
any rejection during the follow-up periods of one 
to six months. There were two deaths. The 13 
patients pretreated for 17 to 23 days exhibited 
stronger cytotoxic antibody responsiveness, and 
five of these recipients had significant rejections 
of which four were reversible. One of the latter 
13 patients died. These clinical and immunologic 
studies have established the value and have de-
fined the appropriate timing of preoperative tho-
racic duct drainage in kidney transplantation. 
They have also directed attention to the rationale 
and the probable value of using other immuno-
suppressive methods for preparatory host condi-
tioning instead of beginning such therapy at the 
time of transplantation. 
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